The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
|Videos|October 18, 2017
Dr. Maloney Discusses Excitement With CAR T-Cell Therapy
Author(s)David G. Maloney, MD, PhD
David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, Washington, discusses excitement with CAR T-cell therapy.
Advertisement
David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, Washington, discusses excitement with chimeric antigen receptor (CAR) T-cell therapy.
With the recent FDA approval of tisagenlecleucel (Kymriah) in acute lymphocytic leukemia (ALL), there has been a lot of buzz about CAR T cell-therapy in hematologic malignancies.
Advertisement
Related to this article
The FDA set a PDUFA target action date of March 31, 2027, for tabelecleucel in relapsed or refractory EBV-positive posttransplant lymphoproliferative disease.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
3
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
4
HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management
5